Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Our new book is a comprehensive look at a vital part of medicines development and regulatory affairs. Grab your copy today!
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
| 19 March 2014 | By Louise Zornoza,
At a hearing on enhancing pharmaceutical research in Brazil, the chair of the Senate Social Affairs Committee, Senator Waldemir Moka, called for the creation of a working group of government agencies and academic researchers who would prepare proposals on ways to bring multi-country clinical trials to Brazil.
Another Senator, Ana Amelia, noted the possible need to revise the existing legal framework governing the conduct of clinical trials in the country, if necessary.
In response, the CEO of Anvisa, Dirceu Barbano, said it is important to improve the timeframes for the approval of clinical trials, but that that it is also important to ensure the rights and safety of clinical trial subjects. Barbano added that the issue of enhancing Brazil as a site for clinical trials would be discussed this year, as part of the agency's Regulatory Agenda for 2013/2014.
Read all Breaking News at RegLink
Tags: DIrceu Barbano, South America, brazil, clinical trials